ISRCTN31825442已完成不适用
Prostate Cancer Antigen 3 (PCA3) and functional Magnetic Resonance Imaging (MRI) in prostate cancer diagnosis: A prospective multicentre study
ational Cancer Institute (Istituto Nazionale Tumori [INT]) - G Pascale Foundation (Fondazione G. Pascale) (Italy)0 个研究点目标入组 1,000 人开始时间: 2010年3月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- Male
入选标准
- •1. Age >45 yrs
- •2. Able to comply with the protocol procedures
- •3. Able to understand and give consent to the protocol procedures
- •4. Indication for prostate biopsy or re-biopsy based on clinical parameters and prostate-specific antigen (PSA) values
排除标准
- •1. PSA > 10 ng/ml
- •2. Therapy with finasteride or dutasteride in the previous 6 months
- •3. Unable to follow the protocol procedures and to give informed consent
- •4. Recent history of drug or alcohol abuse
研究者
相似试验
进行中（未招募）
不适用
A clinical study to access the change in the score of two biomarkers in patients who are begining treatment with androgen deprivatin therapy (Triptorelin 22.5mg) that have advanced prosate cancer.ocally advanced or metastatic prostate cancerMedDRA version: 14.1Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012786-58-LTIpsen Pharma315
进行中（未招募）
1 期
A clinical study to access the change in the score of two biomarkers in patients who are begining treatment with androgen deprivatin therapy (Triptorelin 22.5mg) that have advanced prosate cancer.EUCTR2009-012786-58-BEIpsen Pharma315
进行中（未招募）
不适用
A clinical study to access the change in the score of two biomarkers in patients who are begining treatment with androgen deprivatin therapy (Triptorelin 22.5mg) that have advanced prosate cancer.ocally advanced or metastatic prostate cancerMedDRA version: 14.1Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012786-58-NLIpsen Pharma315
进行中（未招募）
不适用
PROSTATE CANCER ANTIGEN-3 (PCA-3) AND TMPRSS2-ERG (T2-ERG) SCORE CHANGES DURING INITIATION OF ANDROGEN DEPRIVATION THERAPY (ADT) WITH TRIPTORELIN 22.5MG IN PATIENTS WITH ADVANCED PROSTATE CANCER (PCA): A PHASE III, SINGLE ARM MULTICENTRE STUDY.ocally advanced or metastatic prostate cancerMedDRA version: 12.0Level: PTClassification code 10060862Term: Prostate cancerEUCTR2009-012786-58-LVIpsen Pharma SAS315
进行中（未招募）
1 期
PROSTATE CANCER ANTIGEN-3 (PCA-3) AND TMPRSS2-ERG (T2-ERG) SCORE CHANGES DURING INITIATION OF ANDROGEN DEPRIVATION THERAPY (ADT) WITH TRIPTORELIN 22.5MG IN PATIENTS WITH ADVANCED PROSTATE CANCER (PCA): A PHASE III, SINGLE ARM MULTICENTRE STUDY.ocally advanced or metastatic prostate cancerMedDRA version: 12.0Level: PTClassification code 10060862Term: Prostate cancerEUCTR2009-012786-58-FRIpsen Pharma SAS325